Clinical Trial

Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies

Name: Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies — clinical trial record (NCT07284927)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This clinical trial is designed as a single-arm, open-label, single-center, investigator-initiated, early-phase study. Its primary objective is to evaluate the safety of LV009 Injection in subjects with relapsed/refractory CD19-positive hematolymphoid malignancies.

Trial Details

NCT Number	NCT07284927
Lead Sponsor	PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Conditions	Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Enrollment	10 participants
Start Date	2025-12-03
Primary Completion	2026-12-03 (estimated)
Study Completion	2027-12-03 (estimated)
Updated on ClinicalTrials.gov	2025-12-16